 NEW YORK, June 28, 2021 PRNewswire -- Seelos Therapeutics, Inc. Nasdaq: SEEL, a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced it has been added to the Russell 2000, Russell 3000 and Russell Microcap Indexes effective after the U.S. markets open today, June 28, 2021, as part of the 2021 Russell US Indexes Reconstitution. The inclusion of Seelos into the Russell 2000, 3000 and microcap indexes should help increase our exposure in the investment community and is a tribute to the progress we have made building the company over the past year, said Raj Mehra, PhD, Chairman and CEO of Seelos. 